Senores Pharmaceuticals IPO To Open For Subscription on December 20

The ₹582.11 crore Senores Pharmaceuticals IPO is set to open for bidding on December 20, 2024 and closes on December 24, 2024. This upcoming IPO is a combination of a fresh issue of 1.28 crore shares aggregating to ₹500.00 crore and an offer for sale of 0.21 crore shares aggregating to ₹82.11 crore. Senores Pharmaceuticals IPO allotment is likely to be finalised on December 26, 2024, and will be listed on BSE and NSE with a tentative listing date of December 30, 2024.

The price band for Senores Pharmaceuticals IPO has been fixed at ₹372 to ₹391 per share. The minimum lot size for an application is 38. The minimum amount of investment required by retail investors is ₹14,858.

Purpose of Senores Pharmaceuticals IPO

The company proposes to use the net proceeds towards funding the following objects:

• Investment in one of the Subsidiaries, Havix Group, Inc. d/b/aAavis Pharmaceuticals(“Havix”), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility;
• Repayment/pre-payment, in full or in part, of certain borrowings availed by the Company;
• Investment in the Subsidiary, namely, Havix, for re-payment/pre-payment in whole or part of certain borrowings availed by such Subsidiary;
• Funding the working capital requirements of the Company;
• Investment in the Subsidiaries, namely, Senores Pharmaceuticals Inc. (“SPI”)and Ratnatris Pharmaceutical Private Limited (“Ratnatris”), to fund their working capital requirements.
• Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.

About Senores Pharmaceuticals Limited

Founded in December 2017, Senores Pharmaceuticals Limited specializes in the development and manufacturing of a diverse range of pharmaceutical products, primarily targeting regulated markets such as the US, Canada, and the UK, alongside serving emerging markets.

The company’s product portfolio includes Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Butalbital, Acetaminophen and Caffeine Capsules, Mexiletine Hydrochloride Capsules, Ketorolac Tromethamine Tablets, and more. As of September 30, 2024, Senores Pharmaceuticals has launched 55 products across key therapeutic areas, including antibiotics and antifungal treatments.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.